Nanobubbles as theranostic platforms for tumour-specific imaging and therapy

Sandip Prasad Tiwari

doi:10.53730/ijhs.v6nS2.7942

Authors

Sandip Prasad Tiwari Kalinga University, Faculty of Pharmacy, Kotni, Naya Raipur, Chhattisgarh, India

Keywords:

nano carriers, multifunctional nanoparticles, theranostics, malignant growth, nanomaterials, picture directed treatment

Abstract

Effective disease the executives relies upon precise diagnostics alongside explicit treatment conventions. Current analytic procedures should be improved towards give prior discovery abilities, also customary chemotherapy ways towards deal with disease treatment are restricted by absence of explicitness also foundational harmfulness. This audit features propels in nanotechnology that have permitted the improvement of multifunctional stages for malignant growth discovery, treatment, also checking. Nanomaterial’s can be utilized as MRI, optical imaging, furthermore, photo acoustic imaging contrast specialists. When utilized as medication transporters, Nano formulations can increment growth openness towards remedial specialists also result in superior treatment impacts by dragging out flow times, shielding entangled drugs from corruption, also improving cancer take-up through the upgraded porousness also maintenance impact also as receptor-interceded endocytosis. Numerous restorative specialists like chemotherapy, antiangiogenic, or quality treatment specialists can be all the while conveyed by Nano carriers towards growth locales towards improve the adequacy of treatment. Moreover, imaging also treatment specialists can be co-conveyed towards give consistent combination of diagnostics, treatment, also follow-up, also different helpful modalities, for example, chemotherapy also hyperthermia can be co-controlled towards exploit synergistic impacts.

Downloads

Download data is not yet available.

References

Acharya, S., &Sahoo, S. K. (2011). Advanced Drug Delivery Reviews, 63, 170–183.

Aktas, Y., Andrieux, K., Alonso, M. J., et al. (2005). International Journal of Pharmaceutics, 298, 378–383. 52. Karatas, H., Aktas, Y., Gursoy-Ozdemir, Y., et al. (2009). Journal of Neuroscience, 29, 13761–13769. ApplBiochemBiotechnol (2011) 165:1628–1651 1647

Allen, T. M. (1994). Advanced Drug Delivery Reviews, 13, 285–309.

Anderson, J. M., &Shive, M. S. (1997). Advanced Drug Delivery Reviews, 28, 5–24. 37. Birrenbach, G. S. P. (1976). Journal of Pharmaceutical Sciences, 65, 1763.

Avgoustakis, K. (2004). Current Drug Delivery, 1, 321–333. 39. Fahmy, T. M., Fong, P. M., Goyal, A., & Saltzman, W. M. (2005). Materials Today, 8, 18–26.

Axelsson, B. (1989). Advanced Drug Delivery Reviews, 3, 391–404.

Bakker-Woudenberg, I., Lokerse, A., ten Kate, M., et al. (1993). European Journal of Clinical Microbiology, 12, S61–S67.

Baldrick, P. (2010). Regulatory Toxicology also Pharmacology, 56, 290–299.

Banerjee, R. (2001). Journal of Biomaterials Applications, 16, 3–21.

Bhardwaj, V., Ankola, D. D., Gupta, S. C., et al. (2009). Pharmaceutical Research, 26, 2495–2503. 68. Gradishar, W. J., Tjuladin, S., Davidson, N., Shaw, H., Desai, N., Bhar, P., et al. (2005). J ClinOncol, 23, 7794–7803.

Blume, G., Cevc, G., Crommelin, M. D. J. A., et al. (1993). BBA Review Biomembranes, 1149, 180– 184.

Brandl, M. (2001). Biotechnology Annual Review, 7, 59–85.

Breimer, D. D. (1998). Advanced Drug Delivery Reviews, 33, 265–268.

Burger, J. J., Tomlinson, E., Mulder, E. M. A., &McVie, J. G. (1985). International Journal of Pharmaceutics, 23, 333–344.

Cattel, L., Ceruti, M., &Dosio, F. (2003). Tumori, 89, 237–249. 27. Salzberg, M., Thurlimann, B., Bonnefois, H., et al. (2005). Oncology, 68, 293–298.

Cheung, T. W., Remick, S. C., Azarnia, N., et al. (1999). Clinical Cancer Research, 5, 3432–3437.

Chhikara, B. S., &Parang, K. (2010). Expert Opinion on Drug Delivery, 7, 1399–1414.

Chung, Y. I., Kim, J. C., Kim, Y. H., et al. (2010). Journal of Controlled Release, 143, 374–382. 41. Nicolas, J., &Couvreur, P. (2009). Wiley Interdisciplinary Reviews: Nanomedicine also Nanobiotechnology, 1, 111–127.

Corsi, K., Chellat, F., Yahia, L., &Fernandes, J. C. (2003). Biomaterials, 24, 1255–1264.

Dash, M., Chiellini, F., Ottenbrite, R., &Chiellini, E. (2011). Progress in Polymer Science, 36, 981– 1014.

Day, E. S., Morton, J. G., & West, J. L. (2009). Journal of Biomechanical Engineering, 131, 074001.

de Estella-Hermoso, M. A., Campanero, M. A., Mollinedo, F., & Blanco-Prieto, M. J. (2009). Journal of Biomedical Nanotechnology, 5, 323–343.

Dorshow, R. B., Bugaj, J. E., & Burleigh, B. D. (1998). Journal of Biomedical Optics, 3, 340–345.

Ehlrich, P. (1906). Collected studies on immunity (pp. 404–443). New York: Wiley.

Erbacher, P., Zou, S., Bettinger, T., et al. (1998). Pharmaceutical Research, 15, 1332–1339.

Fassas, A., &Anagnostopoulos, A. (2005). Leukemia & Lymphoma, 46, 795–802.

Fernandez-Fernandez, A., Manchanda, R., Lei, T., et al. (2011). Comparative study of the optical also heat generation properties of IR820 also indocyanine green. Molecular Imaging, [Epub ahead of print].

Gregoriadis, G., & Ryman, B. E. (1972). European Journal of Biochemistry, 24, 485–491.

Gregoriadis, G., Leathwood, P. D., & Ryman, B. E. (1971). FEBS Letters, 14, 95–99.

Hirsch, L. R., Stafford, R. J., Bankson, J. A., et al. (2003). Proceedings of the National Academy of Sciences of the United States of America, 100, 13549–13554.

Hwang, H. Y., Kim, I. S., Kwon, I. C., & Kim, Y. H. (2008). Journal of Controlled Release, 128, 23– 31. 59. Ohya, Y., Takei, T., Kobayashi, H., &Ouchi, T. (1993). Journal of Microencapsulation, 10, 1–9.

Janes, K. A., Fresneau, M. P., Marazuela, A., et al. (2001). Journal of Controlled Release, 73, 255–267. 56. Lee, E., Lee, J., Lee, I. H., et al. (2008). Journal of Medicinal Chemistry, 51, 6442–6449.

Jayakumar, R., Prabaharan, M., Nair, S. V., & Tamura, H. (2010). Biotechnology Advances, 28, 142–150.

Jemal, A., Siegel, R., Xu, J., & Ward, E. (2010). A Cancer Journal for Clinicians, 60, 267–300.

Johansen, P. L. (1990). European Heart Journal, 11(Suppl I), 6–12.

Kievit, F. M., Veiseh, O., Bhattarai, N., et al. (2009). Advanced Functional Materials, 19, 2244–2251.

Koukourakis, M. I., Koukouraki, S., Giatromanolaki, A., et al. (1999). Journal of Clinical Oncology, 17, 3512–3521. 30. Caponigro, F., Comella, P., Budillon, A., et al. (2000). Annals of Oncology, 11, 339–34232.

Kreuter, J. (1996). Journal of Anatomy, 189(Pt 3), 503–505.

Kumar, M., Behera, A. K., Lockey, R. F., et al. (2002). Human Gene Therapy, 13, 1415–1425.

Kumari, A., Yadav, S. K., &Yadav, S. C. (2009). Colloid Surface B, 75, 1–18. 43. Nagpal, K., Singh, S. K., & Mishra, D. N. (2010). Chemical also Pharmaceutical Bulletin (Tokyo), 58, 1423–1430.

Lee, J. H., Jung, S. W., Kim, I. S., et al. (2003). International Journal of Pharmaceutics, 251, 23–32.

Lestini, B. J., Sagnella, S. M., Xu, Z., et al. (2002). Journal of Controlled Release, 78, 235–247.

Liu, Z. H., Jiao, Y. P., Wang, Y. F., et al. (2008). Advanced Drug Delivery Reviews, 60, 1650–1662.

Manchanda, R., Fernandez-Fernandez, A., Nagesetti, A., &McGoron, A. J. (2010). Colloid Surface B, 75, 260–267

Matsumura, Y., Hamaguchi, T., Ura, T., et al. (2004). British Journal of Cancer, 91, 1775–1781.

Min, K. H., Park, K., Kim, Y. S., et al. (2008). Journal of Controlled Release, 127, 208–218.

Mori, A., Klibanov, A. L., Torchilin, V. P., & Huang, L. (1991). FEBS Letters, 284, 263–266.

Nam, T., Park, S., Lee, S. Y., et al. (2010). Bioconjugate Chemistry, 21, 578–582.

Nelken, N., & Schneider, P. A. (2004). Surgical Clinics of North America, 84, 1203–1236.

O’Neal, D. P., Hirsch, L. R., Halas, N. J., et al. (2004). Cancer Letters, 209, 171–176.

Park, H., Yang, J., Lee, J., et al. (2009). ACS Nano, 3, 2919–2926. 159. Wust, P., Gneveckow, U., Johannsen, M., et al. (2006). International Journal of Hyperthermia, 22, 673–685.

Park, J., Fong, P. M., Lu, J., et al. (2009). Nanomedicine, 5, 410–418.

Reynolds, C., Barrera, D., Jotte, R., et al. (2009). Journal of Thoracic Oncology, 4, 1537–1543. 70. Nyman, D. W., Campbell, K. J., Hersh, E., et al. (2005). Journal of Clinical Oncology, 23, 7785–7793.

Sapra, P., Tyagi, P., & Allen, T. M. (2005). Current Drug Delivery, 2, 369–381.

Sarris, A. H., Hagemeister, F., Romaguera, J., et al. (2000). Annals of Oncology, 11, 69–72.

Son, Y. J., Jang, J. S., Cho, Y. W., et al. (2003). Journal of Controlled Release, 91, 135–145. 54. Mitra, S., Gaur, U., Ghosh, P. C., &Maitra, A. N. (2001). Journal of Controlled Release, 74, 317–323.

Song, X. R., Cai, Z., Zheng, Y., et al. (2009). European Journal of Pharmaceutical Sciences, 37, 300– 305. 157. Ann-Ann D., Ying-Yi C., Wang C.C., et al. (2008). HER-2 antibody conjugated gold nano rod for in vivo photothermal therapy. In 8th IEEE conference on Nanotechnology NANO’08, 882–885.

Strother, R., &Matei, D. (2009). Therapeutic Clinical Risk Management, 5, 639–650.

Tang, Y., Lei, T., Manchanda, R., et al. (2010). Pharmaceutical Research, 27, 2242–2253.

Tarahovsky, Y. S. (2010). Biochemistry (Mosc), 75, 811–824.

Tripathi, S. K., Goyal, R., Kumar, P., & Gupta, K. C. (2011). Nanomedicine. doi:10.1016/j. nano.2011.06.022.

Wang, X., Li, Y., & Du, Y. (2009). Journal of Nanoscience also Nanotechnology, 9, 6866–6875. 61. Cheong, S. J., Lee, C. M., Kim, S. L., et al. (2009). International Journal of Pharmaceutics, 372, 169– 176.

Wang, X., Wang, Y., Chen, Z. G., & Shin, D. M. (2009). Cancer Research Treatment, 41, 1–11. 1646 ApplBiochemBiotechnol (2011) 165:1628–1651

Xu, Z. P., Zeng, Q. H., Lu, G. Q., & Yu, A. B. (2006). Chemical Engineering Science, 61, 1027–1040. 12. Dakhil, S., Ensminger, W., Cho, K., et al. (1982). Cancer, 50, 631–635.

Yoo, H. S., Lee, K. H., Oh, J. E., & Park, T. G. (2000). Journal of Controlled Release, 68, 419–431.